Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. - Wikidata - awgldk - TriplyDB

Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma.

Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma.

http://www.wikidata.org/entity/Q34128478

about

High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults Consolidative autologous hematopoietic stem-cell transplantation in first remission for non-Hodgkin lymphoma: current indications and future perspective Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation Standard chemotherapy is superior to high-dose chemotherapy with autologous stem cell transplantation on overall survival as the first-line therapy for patients with aggressive non-Hodgkin lymphoma: a meta-analysis.Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning.Toward a Biology-Driven Treatment Strategy for Peripheral T-cell Lymphoma Should eligible patients with T-cell lymphoma receive high-dose therapy and autologous stem cell transplant in the upfront setting?Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorders Current trends in large cell lymphoma.Adult lymphoblastic lymphoma: a retrospective analysis of 92 patients under 61 years included in the LNH87/93 trials.Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.Autologous stem cell transplantation beyond 60 years of age.Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients?FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma.Front-line therapy for nonlocalized diffuse large B-cell lymphoma: what has been demonstrated and what is yet to be established.High dose chemotherapy and autologous stem cell transplantation in non-Hodgkin's lymphoma: an eight-year experience CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial.High dose chemotherapy with autologous stem cell transplantation in diffuse large B-cell lymphoma.First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation.Survival disparities in patients with lymphoma according to place of residence and treatment provider: a population-based study Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma Unresolved issues in diffuse large B-cell lymphomas.Transplantation for non-Hodgkin lymphoma.The role of transplantation in diffuse large B-cell lymphoma: the impact of rituximab plus chemotherapy in first-line and relapsed settings.Hematopoietic cell transplantation for lymphomas.Diffuse large B-cell lymphoma: is there a place for autologous hematopoietic stem cell transplant in first remission in the era of chemo-immunotherapy?The role of hematopoietic SCT in adult Burkitt lymphoma.Current state of art for transplantation paradigms in peripheral T-cell lymphomas.The potential of pralatrexate as a treatment of peripheral T-cell lymphoma.A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas.Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study.Acute renal failure and type B lactic acidosis as first manifestation of extranodal T-cell lymphoblastic lymphoma.The role of autologous stem cell transplantation in the treatment of diffuse large B-cell lymphoma.Favorable Event Free-Survival of High-Dose Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplantation for Higher Risk Diffuse Large B-Cell Lymphoma in First Complete Remission.Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphomas.Autologous stem cell transplantation for aggressive lymphomas.Impact of germinal center and non-germinal center phenotypes on overall and failure-free survival after high-dose chemotherapy and auto-SCT in primary diffuse large B-cell lymphoma.Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma.

P2860

Q24242089-3B9DCEF9-A8B6-4EF8-A89D-85FF0D2959F7 Q26998446-47130426-FAA4-4E2E-8574-77FE3B20FB2C Q28254421-84277D9C-EAAB-4084-8214-B399EDDD3722 Q33550417-311BF926-47A7-4CA5-905C-49868D2D1074 Q33608527-C4E6322C-C51E-4EB0-B801-B6B0259E7B92 Q33670421-2E8AAA32-DE94-4DB1-8885-1FAB6E8D42EA Q33822764-9EA9DAB9-2955-4BA0-9D2E-4EA3B3BE363B Q35040638-C35A6815-315F-4AF2-B075-8BE3055992A8 Q35545076-186540D8-6C65-470B-AD5E-AC468F7B2078 Q35567209-B96DCFD9-C326-4754-9910-EA2CFC11516E Q35626262-561B06C8-B383-4B3F-BB01-1FD7F1995445 Q36591293-93CB0926-633A-475B-9D4A-7D20835072E4 Q36623644-D756DF5C-8D39-42C6-8CE4-ED62A1015778 Q36672691-CCD2409F-7E2B-4727-A368-95D91D3D20B4 Q36838768-F385E7A3-FFC2-4A7E-A853-E021C68BEA0F Q37136999-5C36E8BC-12DF-4352-BBAE-BE49655DA450 Q37205671-01F71D66-6E93-4002-8FB9-3FAD8A1E7656 Q37214534-8C8D0122-88F3-425A-8F7F-3CECD035C326 Q37244089-F037F52D-371C-4EE1-8DB8-A2C5361FA107 Q37271019-9B2F7732-22C6-43CE-AD80-C735A84D995F Q37411665-BD38722B-D020-48A0-B4AD-5CBDD72B055B Q37700942-99F20CE8-E05F-4DA9-9783-70F42C23E7FF Q37705417-ADA86B3B-569E-4E91-B8CE-F8C1EE676362 Q37810079-6852B4AE-E72B-4A22-9B87-7DDD6CA6A611 Q37824456-2AD32AE1-3638-4690-8F89-7C9C4067C506 Q37942817-0EDDE400-A898-46A8-8ECA-6F9A0FBBF1E4 Q37997054-B6EBC0E9-B724-4DF0-86F0-F56C1F8D9EEF Q38031733-1E2694F6-2E80-451B-B8A1-C493B93C742F Q38132821-95926D18-ACC2-4B18-807F-7A9A86B62F9F Q38198754-A9D634F0-01FC-4338-A8D1-1297A2BA902B Q38465823-82C5888D-6B7B-44C1-B38B-33F51D0EE3FC Q38860997-0A359B3E-0F11-4451-8D8E-93274397DF98 Q40459857-E1FFD9A2-9495-426C-9B5F-68930EAC2233 Q40597967-0185DC01-E3FE-46F0-99A7-559D03C1922E Q40795258-90086698-EB26-4CA4-914C-A914616C633B Q41907950-11C85FBF-BC91-4A00-B97B-6C5B85A1DF9C Q41928592-13085EBE-BC29-4119-BCA5-BBC6A69F637A Q42357660-AF56FABF-5EBE-4C2E-9907-FB29B39BCF0D Q45382904-F25E768D-BEF6-4667-B868-229622A6EBBC Q46728532-82103C76-B963-4950-BD8E-BDD795A459BE

P2860

Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma.

http://www.wikidata.org/entity/Q34128478

description

2002 nî lūn-bûn

@nan

2002 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Shortened first-line high-dose ...... prognosis aggressive lymphoma.

@ast

Shortened first-line high-dose ...... prognosis aggressive lymphoma.

@en

Shortened first-line high-dose ...... prognosis aggressive lymphoma.

@nl

type

label

Shortened first-line high-dose ...... prognosis aggressive lymphoma.

@ast

Shortened first-line high-dose ...... prognosis aggressive lymphoma.

@en

Shortened first-line high-dose ...... prognosis aggressive lymphoma.

@nl

prefLabel

Shortened first-line high-dose ...... prognosis aggressive lymphoma.

@ast

Shortened first-line high-dose ...... prognosis aggressive lymphoma.

@en

Shortened first-line high-dose ...... prognosis aggressive lymphoma.

@nl

P1433

Q34128478-9E7A45A7-2FA0-4D2B-A6AD-520B9F51633B

P1476

Q34128478-4125A1EA-0BCC-4879-A0D8-F9CEDCEA9F42

P2093

Q34128478-13780108-B55D-4A24-B9A8-633EDDF9BB36

Q34128478-79E6CC64-883A-461C-AC09-FDA597E30266

Q34128478-94F91211-2A33-489A-A8FD-BC3A644D35FE

Q34128478-98C36580-B232-4186-AB5F-6635B81185FA

Q34128478-9A002D29-1132-49F9-B85F-607C609E720D

Q34128478-A98F857D-121D-4AE4-934B-FFD71F594003

Q34128478-A9D1D1F0-9A8F-437E-B2FD-5213C4C2AFD0

Q34128478-B5D0A80B-8428-432F-8478-053BEC95AB83

Q34128478-BBBC01E7-BECB-4F14-8495-F88C1E12BF52

Q34128478-C1EEB97F-2425-4159-8C83-389E14BCAC52

P304

Q34128478-143C1491-5A01-4B4B-89C1-DCA2E1E7FF6B

P31

Q34128478-4ECB648B-471E-471F-BDCD-8509E0DBB6EA

P356

Q34128478-62802F96-4D08-4CE7-BECC-14EDE003C337

P407

Q34128478-2809395E-AF92-4161-88F9-F68949096F6A

P433

Q34128478-F0E8B35D-5344-4D36-99C7-BF3261602BEE

P478

Q34128478-836386AF-3BA6-42F0-82B1-811AEE06E287

P50

Q34128478-BF7A1130-495F-41DA-87FB-CEA00899A36E

Q34128478-D9FFA03D-EA22-424F-88BC-93A362DF09A1

P577

Q34128478-D7FA1E82-BC0E-45A7-ACB6-50CB8D1F8A47

P698

Q34128478-45C903EB-8DE8-474C-B0DE-A6221464F4B5

P921

Q34128478-73E2FE86-2516-4BA0-B71E-70E4BFBEC2BC

Q34128478-97DDAF9B-AF02-44D0-9B1F-E68DD500246F

P356

JCO.2002.02.125

P1433

Journal of Clinical Oncology

P1476

Shortened first-line high-dose ...... prognosis aggressive lymphoma.

@en

P2093

Bertrand Coiffier

http://www.w3.org/2001/XMLSchema#string

Christian Gisselbrecht

http://www.w3.org/2001/XMLSchema#string

Eric Lepage

http://www.w3.org/2001/XMLSchema#string

Francoise Guilmin

http://www.w3.org/2001/XMLSchema#string

Félix Reyes

http://www.w3.org/2001/XMLSchema#string

Georges Fillet

http://www.w3.org/2001/XMLSchema#string

Groupe d'Etude des Lymphomes de l'Adulte

http://www.w3.org/2001/XMLSchema#string

Hervé Tilly

http://www.w3.org/2001/XMLSchema#string

Jean Gabarre

http://www.w3.org/2001/XMLSchema#string

Pierre Lederlin

http://www.w3.org/2001/XMLSchema#string

P304

2472-2479

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2002.02.125

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Olivier Hermine

P577

2002-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12011124

http://www.w3.org/2001/XMLSchema#string

P921